Latest studies
- RecruitingPHASE3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This study offers ongoing treatment with pelacarsen for people who have finished a previous trial for heart disease. It aims to check the long-term safety of the medicine, which helps lower a type of cholesterol called Lp(a).
Cardiovascular Disease and Lipoprotein(a)Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has specific genetic changes (MSI-H or dMMR). It compares them to standard chemotherapy to see which is better at stopping the cancer from growing.
Microsatellite Instability High (MSI-H) or Mismatch Repair DeficientMetastatic Colorectal Cancer (dMMR)Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study looks at a new medicine called Evolocumab to see if it can lower the chance of serious heart problems like heart attacks or strokes in people at high risk who haven't had them before. It compares Evolocumab to a dummy medicine.
Adults at high risk of cardiovascular events without prior MI or stroke.Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
This study is looking at new treatments for advanced kidney cancer. It compares a combination of two drugs, nivolumab and cabozantinib, against a standard treatment, sunitinib, to see which works better and is safer for people who haven't had treatment before.
Advanced or Metastatic Renal Cell CarcinomaGreece - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
This early-stage study is looking at a new medicine called belantamab mafodotin for people with multiple myeloma. It specifically checks how the medicine works in patients whose liver is healthy compared to those with liver problems. This helps make sure future studies are safe and effective.
Relapsed or Refractory Multiple MyelomaGreece - Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema 2.4 mg/2.4 mg) once weekly versus semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo in people with chronic kidney disease and type 2 diabetes living with overweight or obesity.
This study looks at a new combination medicine, CagriSema, for people with type 2 diabetes, kidney disease, and overweight or obesity. It compares CagriSema to existing treatments and a dummy medicine to see how it affects kidney health, weight, and blood sugar, while checking for side effects.
Chronic Kidney Disease, Type 2 diabetesGreece - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicenter Induction Study with an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
This study is testing a new drug, called Vixarelimab, for adults with moderate to severe ulcerative colitis. It aims to see how well it works to reduce symptoms and improve the gut, as well as checking its safety and how the body handles it.
Ulcerative Colitis (UC)Greece - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)
This study looks at a new medicine, Navitoclax, for people with a blood condition called myelofibrosis. Researchers want to see if it can shrink an enlarged spleen and improve symptoms, either on its own or with another medicine called Ruxolitinib.
MyelofibrosisGreece - RecruitingPhase III
Study evaluating the efficacy of icotrokinra in ulcerative colitis
This study is testing a new medicine, icotrokinra, for ulcerative colitis (UC) in adults and teenagers. It aims to see if icotrokinra can help reduce UC symptoms and keep the disease under control by targeting inflammation.
Ulcerative colitisGreece - Active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
Breast CancerGreece - Active not recruitingPHASE3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study looks at new drug combinations for advanced lung cancer. It compares a new drug (Datopotamab Deruxtecan) with an existing treatment (Pembrolizumab) and chemotherapy, to see if the new combinations are safer and work better.
Metastatic Non Small Cell Lung CancerGreece - Active not recruitingPHASE2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This study is testing a new medicine, Selinexor, for people in the UK with a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded to previous treatments. It aims to see if Selinexor can help when other options haven't worked.
Diffuse Large B-cell LymphomaGreece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
This study is looking at a new way to treat follicular lymphoma, a type of cancer. It compares a drug called Ibrutinib with a standard treatment, Rituximab. The aim is to see if adding Ibrutinib helps people live longer without their cancer getting worse.
Follicular LymphomaGreece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis - EFC17559 / COAST1
This study is testing a new medicine, amlitelimab, for moderate-to-severe eczema in people aged 12 and older. It aims to see how well it clears up skin and reduces itching compared to a dummy treatment, given as an injection.
Dermatitis atopicGreece - RecruitingPHASE3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
This study looks at new ways to treat multiple myeloma. Researchers are testing a drug called elranatamab, alone and with daratumumab, against a standard treatment. The aim is to find better and safer treatments for people who have tried other medicines.
Multiple MyelomaGreece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Therapeutic Non-Inferiority, Randomized, Observer-blind, Active-reference, Two-arm, Parallel Group, Multi-center Clinical Trial for Comparing the Efficacy and Tolerability of a Generic Fixed Combination of Brinzolamide 10mg/ml + Timolol 5mg/ml Eye Drops versus Azarga® 10mg/ml + 5mg/ml Eye Drops in the Treatment of Intraocular Pressure in Patients with Open Angle Glaucoma or Ocular Hypertension
This study compares two eye drop treatments for glaucoma and eye pressure. It checks if a new generic eye drop works just as well as an existing one, Azarga, and how safe they both are for adults with high eye pressure or glaucoma.
Ocular Hypertension, GlaucomaGreece - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer
This study is testing new treatments for advanced non-small cell lung cancer. It combines a new medicine, vudalimab, or an existing one, pembrolizumab, with chemotherapy. Doctors will be looking at how safe and effective these combinations are for patients.
Advanced Non-small Cell Lung CancerGreece - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis
This study is testing a new medicine, Fipaxalparant, for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). Researchers want to see if it's safe and helps improve lung function over one to two years compared to a dummy pill.
Idiopathic Pulmonary FibrosisGreece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047)
This study is testing a new treatment combination for locally advanced cervical cancer. It compares standard chemotherapy and radiation with the same treatment plus a new drug, pembrolizumab (Keytruda), to see if it helps patients live longer and stops the cancer from growing.
Locally Advanced Cervical CancerGreece - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of daxdilimab subcutaneous injection in reducing disease activity in adult participants with moderate-to-severe primary discoid lupus erythematosus.
This study is looking into a new medication called daxdilimab for adults with a type of lupus called discoid lupus erythematosus. Researchers want to see if this medicine can improve skin symptoms and if it's safe to use compared to a dummy treatment.
Primary Discoid Lupus ErythematosusGreece - Ongoing, recruitingTherapeutic exploratory (Phase II)
Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease
This study is testing different new medicines, alone or in combination, to see if they can help improve liver damage and reduce alcohol use in people with liver problems caused by alcohol. One of the medicines is similar to a type already used for diabetes.
alcohol-related liver diseaseGreece - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called Efavaleukin Alfa for people with moderate to severe Ulcerative Colitis. We want to see if it's safe and helps people feel better and get their condition under control within 12 weeks.
Ulcerative Colitis (UC)Greece - Active not recruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study looks at a new drug, efgartigimod PH20 SC, for adults with active idiopathic inflammatory myopathy (IIM), a condition causing muscle weakness and inflammation. It compares the drug to a dummy treatment to see if it helps improve muscle strength and overall well-being.
Active Idiopathic Inflammatory MyopathyMyositisDermatomyositisPolymyositisGreece - Ongoing, recruitingTherapeutic use (Phase IV)
Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight; ADJUST - Phase 4 – efficacy, A randomised, double-blind, controlled, parallel group, multi-centre trial
This study compares a flexible dose of Brodalumab, a psoriasis treatment, with its usual dose for people with moderate to severe plaque psoriasis who weigh 120 kg or more. It aims to see if the adjustable dose works better at clearing skin.
Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaGreece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
This study is looking at a new way to treat AL amyloidosis, a rare condition where unhealthy proteins build up in your body. It compares a new drug called daratumumab with existing treatments to see if it works better and is safe for people newly diagnosed with the condition.
AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)Greece - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Greece - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerGreece - RecruitingPhase I/II
A two-part study to investigate the effects in adults of two doses of golexanolone in patients with primary biliary cholangitis with fatigue and cognitive dysfunction
This study looks at a new drug, golexanolone, for people with a liver condition called Primary Biliary Cholangitis (PBC) who also feel very tired and have trouble thinking clearly. Researchers want to see if it's safe, how it works in the body, and if it helps these symptoms.
Patients with primary biliary cholangitis with fatigue and cognitive dysfunctionGreece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed by Oral Fluconazole (MARIO)
This study looks at new treatments for serious fungal infections called candidemia and invasive candidiasis. We are comparing a new medicine, ibrexafungerp, with an existing one, fluconazole, to see which works better and is safer after initial treatment with another antifungal.
Invasive Candidiasis/ CandidemiaGreece - Active not recruitingPHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy for children and young adults (3-25 years old) with newly diagnosed classical Hodgkin Lymphoma. It specifically focuses on those who aren't responding quickly to initial treatment.
Hodgkin LymphomaGreece - Recruiting
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
This study looks at how well a drug called VITRAKVI works and how safe it is for people with TRK fusion cancer. This type of cancer happens when certain genes fuse together. Doctors want to see how VITRAKVI helps patients in real-world use.
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionGreece - RecruitingPHASE3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
This study looks at a new medicine called zilebesiran for people with high blood pressure that isn't well controlled, especially if they also have heart problems or are at high risk of developing them. The aim is to see if zilebesiran can reduce serious heart-related events like heart attacks or strokes.
High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskGreece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCGreece - RecruitingPHASE2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called brivekimig for moderate to severe hidradenitis suppurativa (HS). It compares brivekimig to a dummy medicine (placebo) to see if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaGreece - Ongoing, recruitingTherapeutic exploratory (Phase II)
Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study
This study is testing a new medicine, NNC0487-0111, for people with type 2 diabetes. It's looking at different ways to take the medicine (once a week shot or once a day pill) to see how safe and effective it is at controlling blood sugar.
Type 2 DiabetesGreece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immunemediated thrombotic thrombocytopenic purpura
This study is testing a new way to treat a rare blood disorder called TTP. It looks at whether a medicine called Cablivi, along with other treatments, can help people with TTP get better without needing a common but intensive procedure called plasma exchange.
Thrombotic Thrombocytopenic PurpuraGreece - RecruitingPHASE3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
This study is testing a new medicine called iptacopan for people aged 12-60 with a kidney disease called C3 Glomerulopathy (C3G). It aims to see if the medicine is safe and helps improve kidney function compared to a dummy pill.
C3GGreece - Active not recruitingPHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
This study looks at new ways to treat advanced non-small cell lung cancer with a specific genetic change. It aims to see if combining a drug called ramucirumab with existing treatments like erlotinib, gefitinib, or osimertinib can work better than current approaches.
Metastatic Non-Small Cell Lung CancerGreece - Recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
This study looks at how a drug called elafibranor works for people with a rare liver disease called Primary Biliary Cholangitis (PBC) in everyday life. Researchers will check its effects, how safe it is, and how well people tolerate it over about five years.
Primary Biliary CholangitisGreece - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaGreece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
This study is comparing a new medicine, JPB898, to a licensed cancer drug called Opdivo. Both are used with another drug, Yervoy, to treat advanced melanoma, a serious type of skin cancer. The aim is to see if JPB898 works just as well and is as safe as Opdivo.
Advanced (unresectable/metastatic) melanomaGreece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
This study is testing a new medicine, secukinumab, for giant cell arteritis (GCA). It compares different doses of secukinumab with a dummy medicine (placebo), alongside a common steroid treatment. The aim is to see if secukinumab can help people with GCA stay well for longer.
Giant cell arteritis (GCA)Greece - Ongoing, recruitingTherapeutic exploratory (Phase II)
Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia
This study is checking a new treatment called Immukine alongside usual care for a serious fungal infection in the blood called candidemia. Researchers want to see if it makes people get better faster and how safe it is.
CandidemiaGreece - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL
This early-stage study is testing a new medicine called JNJ-67856633 in people with specific blood cancers: Non-Hodgkin lymphoma and chronic lymphocytic leukemia. The main goal is to see if the medicine is safe, how it moves through the body, and what effects it has.
Non-Hodgkin lymphoma and chronic lymphocytic leukemiaGreece - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaGreece - Ongoing, recruitingTherapeutic exploratory (Phase II)
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE)
This study looks at a new medicine called paltusotine for people with acromegaly. It's a long-term study to see how safe the medicine is and if it works well over time, especially noting any side effects people might have.
AcromegalyGreece - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
This study investigates a new treatment, CAEL-101, for a serious heart condition called AL amyloidosis. Researchers want to see if CAEL-101 can help patients live longer and reduce hospital stays, alongside their usual medicine, compared to a dummy drug.
AL AmyloidosisGreece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis
This study is testing a new medicine, upadacitinib, for giant cell arteritis (GCA). Researchers want to see if it can help people stay well and reduce the need for steroid medicines, comparing it to a dummy medicine.
Giant Cell ArteritisGreece - Active not recruitingPHASE3
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
This study is looking at a new medicine called Dazodalibep for people with Sjögren's Syndrome. It aims to see how well it helps with symptoms and whether it's safe to use, especially for those with moderate to severe symptoms.
Sjögren's Syndrome (SS)Greece